{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:11:38Z","timestamp":1785510698919,"version":"3.56.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.yrtph.2026.106138","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:25:48Z","timestamp":1780298748000},"page":"106138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study"],"prefix":"10.1016","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6357-1355","authenticated-orcid":false,"given":"Paula","family":"Dominguez-Gomez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zingaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Balzotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Leitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Jacobo-Piqueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Rast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jazmin","family":"Aguado-Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2026.106138_b1","doi-asserted-by":"crossref","DOI":"10.1080\/15376516.2016.1256460","article-title":"Early assessment of proarrhythmic risk of drugs using the in vitro data and single-cell-based in silico models: proof of concept","author":"Abbasi","year":"2017","journal-title":"Toxicol. Mech. Methods"},{"key":"10.1016\/j.yrtph.2026.106138_b2","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2024.107498","article-title":"Virtual clinical QT exposure-response studies \u2013 A translational computational approach","author":"Aguado-Sierra","year":"2024","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2026.106138_b3","doi-asserted-by":"crossref","DOI":"10.1111\/anec.12505","article-title":"Loperamide cardiotoxicity: \u201ca brief review\u201d","author":"Akel","year":"2018","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"10.1016\/j.yrtph.2026.106138_b4","doi-asserted-by":"crossref","DOI":"10.1177\/00368504251344145","article-title":"The computational model lifecycle: Opportunities and challenges for computational medicine in the healthcare ecosystem","author":"Bridio","year":"2025","journal-title":"Sci. Prog."},{"key":"10.1016\/j.yrtph.2026.106138_b5","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2016.03.009","article-title":"An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel","author":"Crumb","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2026.106138_b6","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.12201","article-title":"Are women more susceptible than men to drug-induced QT prolongation? concentration\u2013QTc modelling in a phase 1 study with oral rac-sotalol","author":"Darpo","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106138_b7","article-title":"Replicating clinical placebo effects in computational trials: Bridging the gap between in silico and clinical studies","author":"Dominguez-Gomez","year":"2025","journal-title":"J. Precis. Med.: Health Dis."},{"key":"10.1016\/j.yrtph.2026.106138_b8","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxrep.2025.102179","article-title":"Can in silico models predict drug-induced cardiac risk in vulnerable populations?","author":"Dominguez-Gomez","year":"2026","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.yrtph.2026.106138_b9","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-024-01370-8","article-title":"Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators","author":"Dominguez-Gomez","year":"2024","journal-title":"Npj Digit. Med."},{"key":"10.1016\/j.yrtph.2026.106138_b10","series-title":"Loperamide: Uses, interactions, mechanism of action","author":"DrugBank","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106138_b11","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2013.04.007","article-title":"Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment","author":"Elkins","year":"2013","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2026.106138_b12","article-title":"Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety","author":"Goldring","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yrtph.2026.106138_b13","article-title":"Ventricular anatomical complexity and sex differences impact predictions from electrophysiological computational models","author":"Gonzalez-Martin","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.yrtph.2026.106138_b14","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.91911.3.sa3","article-title":"Neural network emulation of the human ventricular cardiomyocyte action potential for more efficient computations in pharmacological studies","author":"Grandits","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.yrtph.2026.106138_b15","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2019.01139","article-title":"Three-dimensional heart model-based screening of proarrhythmic potential by in silico simulation of action potential and electrocardiograms","author":"Hwang","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.yrtph.2026.106138_b16","article-title":"Sex-specific classification of drug-induced Torsade de Pointes susceptibility using cardiac simulations and machine learning","author":"Iseppe","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2026.106138_b17","doi-asserted-by":"crossref","DOI":"10.1007\/s10928-025-09985-4","article-title":"FDA\u2019s insights: implementing new strategies for evaluating drug-induced QTc prolongation","author":"Ji","year":"2025","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.yrtph.2026.106138_b18","doi-asserted-by":"crossref","DOI":"10.1007\/s00210-016-1286-7","article-title":"Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic","author":"Kang","year":"2016","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106138_b19","doi-asserted-by":"crossref","DOI":"10.3390\/jcdd9120431","article-title":"Risk of cardiac lesion with chronic and acute use of loperamide\u2014An integrative review","author":"Lammoglia","year":"2022","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"10.1016\/j.yrtph.2026.106138_b20","doi-asserted-by":"crossref","DOI":"10.1080\/15563650.2018.1510128","article-title":"Loperamide misuse to avoid opioid withdrawal and to achieve a euphoric effect: high doses and high risk","author":"Lee","year":"2019","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106138_b21","article-title":"Drug-induced QT prolongation and torsades de pointes","author":"Li","year":"2017","journal-title":"P&T : A Peer-Reviewed J. Formul. Manag."},{"key":"10.1016\/j.yrtph.2026.106138_b22","article-title":"Assessment of an in silico mechanistic model for proarrhythmia risk prediction under the CiPA initiative","author":"Li","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2026.106138_b23","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2023.107860","article-title":"Combining pharmacokinetic and electrophysiological models for early prediction of drug-induced arrhythmogenicity","author":"Llopis-Lorente","year":"2023","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.yrtph.2026.106138_b24","doi-asserted-by":"crossref","DOI":"10.3390\/biom13091355","article-title":"The potential mechanisms behind loperamide-induced cardiac arrhythmias associated with human abuse and extreme overdose","author":"Lu","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.yrtph.2026.106138_b25","doi-asserted-by":"crossref","DOI":"10.3109\/15563650.2014.969371","article-title":"Cardiac conduction disturbance after loperamide abuse","author":"Marraffa","year":"2014","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106138_b26","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvr044","article-title":"Simulation of multiple ion channel block provides improved early prediction of compounds\u2019 clinical torsadogenic risk","author":"Mirams","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.yrtph.2026.106138_b27","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.20744","article-title":"Loperamide-induced cardiac events: Case reports and review","author":"Modi","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.yrtph.2026.106138_b28","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4061980","article-title":"Loperamide induced torsades de pointes: A case report and review of the literature","author":"Mukarram","year":"2016","journal-title":"Case Rep. Med."},{"key":"10.1016\/j.yrtph.2026.106138_b29","doi-asserted-by":"crossref","DOI":"10.1080\/15563650.2025.2459763","article-title":"Loperamide-induced severe cardiotoxicity: a toxicokinetic and toxicodynamic analysis derived from a case series and the published literature","author":"Nic Ionmhain","year":"2025","journal-title":"Clinical Toxicology"},{"key":"10.1016\/j.yrtph.2026.106138_b30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002061","article-title":"Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation","author":"O\u2019Hara","year":"2011","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.yrtph.2026.106138_b31","doi-asserted-by":"crossref","DOI":"10.1111\/bph.14357","article-title":"Arrhythmic hazard map for a 3D whole-ventricle model under multiple ion channel block","author":"Okada","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106138_b32","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2017.00668","article-title":"Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity","author":"Passini","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.yrtph.2026.106138_b33","doi-asserted-by":"crossref","DOI":"10.1016\/j.yjmcc.2015.09.003","article-title":"Mechanisms of pro-arrhythmic abnormalities in ventricular repolarisation and anti-arrhythmic therapies in human hypertrophic cardiomyopathy","author":"Passini","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.yrtph.2026.106138_b34","doi-asserted-by":"crossref","DOI":"10.1111\/bph.14786","article-title":"Drug-induced shortening of the electromechanical window is an effective biomarker for in silico prediction of clinical risk of arrhythmias","author":"Passini","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106138_b35","article-title":"Sex matters: A comprehensive comparison of female and male hearts","author":"Peirlinck","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.yrtph.2026.106138_b36","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.708435","article-title":"Sex differences in drug-induced arrhythmogenesis","author":"Peirlinck","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.yrtph.2026.106138_b37","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2014.08.001","article-title":"Solubility assessment and on-line exposure confirmation in a patch-clamp assay for hERG (human ether-a-go-go-related gene) potassium channel inhibition","author":"Rast","year":"2014","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2026.106138_b38","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbs.2021.108593","article-title":"To sobol or not to sobol? The effects of sampling schemes in systems biology applications","author":"Renardy","year":"2021","journal-title":"Math. Biosci."},{"key":"10.1016\/j.yrtph.2026.106138_b39","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jcim.7b00440","article-title":"In silico QT and APD prolongation assay for early screening of drug-induced proarrhythmic risk","author":"Romero","year":"2018","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.yrtph.2026.106138_b40","doi-asserted-by":"crossref","DOI":"10.1016\/j.cma.2019.01.033","article-title":"Machine learning in drug development: Characterizing the effect of 30 drugs on the QT interval using Gaussian process regression, sensitivity analysis, and uncertainty quantification","author":"Sahli Costabal","year":"2019","journal-title":"Comput. Methods Appl. Mech. Engrg."},{"key":"10.1016\/j.yrtph.2026.106138_b41","doi-asserted-by":"crossref","DOI":"10.1002\/cnm.2964","article-title":"Predicting drug-induced arrhythmias by multiscale modeling","author":"Sahli Costabal","year":"2018","journal-title":"Int. J. Numer. Methods Biomed. Eng."},{"key":"10.1016\/j.yrtph.2026.106138_b42","series-title":"Global Sensitivity Analysis: The Primer","author":"Saltelli","year":"2008"},{"key":"10.1016\/j.yrtph.2026.106138_b43","doi-asserted-by":"crossref","DOI":"10.1002\/cnm.3140","article-title":"Fully coupled fluid-electro-mechanical model of the human heart for supercomputers","author":"Santiago","year":"2018","journal-title":"Int. J. Numer. Methods Biomed. Eng."},{"key":"10.1016\/j.yrtph.2026.106138_b44","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2125.2002.01627.x","article-title":"The significance of QT interval in drug development","author":"Shah","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106138_b45","doi-asserted-by":"crossref","DOI":"10.1039\/9781849731102","article-title":"The effect of plasma protein binding on in vivo efficacy: Misconceptions in drug discovery","author":"Smith","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yrtph.2026.106138_b46","doi-asserted-by":"crossref","DOI":"10.1152\/physrev.00017.2023","article-title":"Computational modeling of cardiac electrophysiology and arrhythmogenesis: toward clinical translation","author":"Trayanova","year":"2024","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.yrtph.2026.106138_b47","doi-asserted-by":"crossref","DOI":"10.1016\/j.annemergmed.2016.08.444","article-title":"Epidemiologic trends in loperamide abuse and misuse","author":"Vakkalanka","year":"2017","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.yrtph.2026.106138_b48","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.2029","article-title":"Time for a fully integrated nonclinical\u2013clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective","author":"Vargas","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2026.106138_b49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocs.2015.12.007","article-title":"Alya: Multiphysics engineering simulation toward exascale","author":"V\u00e1zquez","year":"2016","journal-title":"J. Comput. Sci."},{"key":"10.1016\/j.yrtph.2026.106138_b50","article-title":"Impact of amiodarone and cisapride on simulated human ventricular electrophysiology and electrocardiograms","author":"Wilhelms","year":"2012","journal-title":"EP Eur."},{"key":"10.1016\/j.yrtph.2026.106138_b51","doi-asserted-by":"crossref","DOI":"10.1111\/j.1476-5381.2012.02200.x","article-title":"Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials","author":"Zemzemi","year":"2013","journal-title":"Br. J. Pharmacol."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027323002600111X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027323002600111X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:35:16Z","timestamp":1785508516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027323002600111X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":51,"alternative-id":["S027323002600111X"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106138","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106138"}}